This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond) 2017; 31: 241-57. doi: 10.1038/eye.2016.275KalikiSShieldsCLUveal melanoma: relatively rare but deadly cancer2017312415710.1038/eye.2016.275530646327911450Open DOISearch in Google Scholar
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 2020; 144: 500-22. doi: 10.5858/arpa.2019-0561-RAElderDEBastianBCCreeIAMassiDScolyerRAThe 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway20201445002210.5858/arpa.2019-0561-RA32057276Open DOISearch in Google Scholar
Sathe S, Sakata M, Beaton AR, Sack RA. Identification, origins and the diurnal role of the principal serine protease inhibitors in human tear fluid. Curr Eye Res 1998; 17: 348-62. doi: 10.1080/02713689808951215SatheSSakataMBeatonARSackRAIdentification, origins and the diurnal role of the principal serine protease inhibitors in human tear fluid1998173486210.1080/027136898089512159561826Open DOISearch in Google Scholar
Saakyan SV, Tsygankov АY, Moiseeva NI, Karamysheva АF, Garri DD. Assessment of the chemosensitivity of uveal melanoma cells ex vivoBull Exp Biol Med 2020; 170: 142-7. doi: 10.1007/s10517-020-05020-3SaakyanSVTsygankovАY, Moiseeva NIKaramyshevaАF, Garri DDAssessment of the chemosensitivity of uveal melanoma cells ex vivo2020170142710.1007/s10517-020-05020-333231795Open DOISearch in Google Scholar
Shah SU, Mashayekhi A, Shields CL, Walia HS, Hubbard GB 3rd, Zhang J, et al. Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology 2014; 121: 352-7. doi: 10.1016/j. ophtha.2013.07.014ShahSUMashayekhiAShieldsCLWaliaHSHubbardGB 3rdZhangJetalUveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients2014121352710.1016/j.ophtha.2013.07.01423988200Open DOISearch in Google Scholar
Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, et al. Adjuvant sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls. Ophthalmology 2018; 125: 210-7. doi: 10.1016/j. ophtha.2017.08.017ValsecchiMEOrloffMSatoRChervonevaIShieldsCLShieldsJAet alAdjuvant sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls2018125210710.1016/j.ophtha.2017.08.01728935400Open DOISearch in Google Scholar
Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev 2012; 38: 549-53. doi: 10.1016/j.ctrv.2012.01.002SpagnoloFCaltabianoGQueiroloPUveal melanoma2012385495310.1016/j.ctrv.2012.01.00222270078Open DOISearch in Google Scholar
Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2015; 28: 135-47. doi: 10.1111/ pcmr.12304LukeJJTriozziPLMcKennaKCVanMeir EGGershenwaldJEBastianBCet alBiology of advanced uveal melanoma and next steps for clinical therapeutics2015281354710.1111/pcmr.12304432663725113308Open DOISearch in Google Scholar
Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 2008; 13: 5406-20. doi: 10.2741/3089TurkVStokaVTurkDCystatins: biochemical and structural properties, and medical relevance20081354062010.2741/308918508595Open DOISearch in Google Scholar
Breznik B, Mitrović A, Lah T, Kos J. Cystatins in cancer progression: more than just cathepsin inhibitors. Biochimie 2019; 166: 233-50. doi: 10.1016/j. biochi.2019.05.002BreznikBMitrovićALahTKosJCystatins in cancer progression: more than just cathepsin inhibitors20191662335010.1016/j.biochi.2019.05.00231071357Open DOISearch in Google Scholar
Wu H, Du Q, Dai Q, Ge J, Cheng X. Cysteine protease cathepsins in atherosclerotic cardiovascular diseases. J Atheroscler Thromb 2018; 25: 111-23. doi: 10.5551/jat.RV17016WuHDuQDaiQGeJChengXCysteine protease cathepsins in atherosclerotic cardiovascular diseases2018251112310.5551/jat.RV17016Open DOISearch in Google Scholar
Wallin H, Bjarnadottir M, Vogel LK, Wassélius J, Ekström U, Abrahamson M. Cystatins – extra- and intracellular cysteine protease inhibitors: high-level secretion and uptake of cystatin C in human neuroblastoma cells. Biochimie 2010; 92: 1625-34. doi: 10.1016/j.biochi.2010.08.011WallinHBjarnadottirMVogelLKWasséliusJEkströmUAbrahamsonMCystatins – extra- and intracellular cysteine protease inhibitors: high-level secretion and uptake of cystatin C in human neuroblastoma cells20109216253410.1016/j.biochi.2010.08.011Open DOISearch in Google Scholar
Liu Y, Yao J. Research progress of cystatin SN in cancer. Onco Targets Ther 2019; 12: 3411-9. doi: 10.2147/OTT.S194332LiuYYaoJResearch progress of cystatin SN in cancer2019123411910.2147/OTT.S194332Open DOISearch in Google Scholar
Grubb AO. Cystatin C – properties and use as diagnostic marker. Adv Clin Chem 2000; 35: 63-99. doi: 10.1016/s0065-2423(01)35015-1GrubbAOCystatin C – properties and use as diagnostic marker200035639910.1016/s0065-2423(01)35015-1Open DOISearch in Google Scholar
Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp 2003; 70: 179-99. doi: 10.1042/bss0700179AbrahamsonMAlvarez-FernandezMNathansonCMCystatins2003701799910.1042/bss070017914587292Open DOISearch in Google Scholar
Poteryaeva ON, Falameyeva OV, Korolenko TA, Kaledin VI, Djanayeva SJ, Nowicky JW, et al. Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. Drugs Exp Clin Res 2000; 26: 301-6. PMID: 11345042PoteryaevaONFalameyevaOVKorolenkoTAKaledinVIDjanayevaSJNowickyJWet alCysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice2000263016PMID: 11345042Search in Google Scholar
Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 2006; 235: 159-76. doi: 10.1016/j.canlet.2005.04.001KepplerDTowards novel anti-cancer strategies based on cystatin function20062351597610.1016/j.canlet.2005.04.00115893421Open DOISearch in Google Scholar
Lah TT, Kokalj-Kunovar M, Drobnic-Kosorok M, Babnik J, Golouh R, Vrhovec I, et al. Cystatins and cathepsins in breast carcinoma. Biol Chem Hoppe Seyler 1992; 373: 595-604. doi: 10.1515/bchm3.1992.373.2.595LahTTKokalj-KunovarMDrobnic-KosorokMBabnikJGolouhRVrhovecIet alCystatins and cathepsins in breast carcinoma199237359560410.1515/bchm3.1992.373.2.5951515089Open DOISearch in Google Scholar
Cox JL. Cystatins and cancer. Front Biosci (Landmark Ed) 2009; 14: 463-74. doi: 10.2741/3255. PMID: 19273078CoxJLCystatins and cancer2009144637410.2741/3255.PMID:19273078Open DOISearch in Google Scholar
Jakoš T, Pišlar A, Jewett A, Kos J. Cysteine cathepsins in tumor-associated immune cells. Front Immunol 2019; 10: 2037. doi: 10.3389/fimmu.2019.02037JakošTPišlarAJewettAKosJCysteine cathepsins in tumor-associated immune cells201910203710.3389/fimmu.2019.02037672455531555270Open DOISearch in Google Scholar
Svechnikova IG, Korolenko TA, Stashko JuF, Kaledin VI, Nikolin VP, Nowicky JW. The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy. Drugs Exp Clin Res 1998; 24: 261-9. PMID: 10190085SvechnikovaIGKorolenkoTAStashkoJuFKaledinVINikolinVPNowickyJWThe influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy1998242619PMID: 10190085Search in Google Scholar
Korolenko TA, Cherkanova MS, Gashenko EA, Johnston T. Cystatin C, atherosclerosis and lipid-lowering therapy by statins. In: Cohen JB, Ryseck LP, editors. Cystatins: protease inhibitors, biomarkers and immunomodulators. New York, USA: Nova Science Publishers; 2011. p. 187-204.KorolenkoTACherkanovaMSGashenkoEAJohnstonTCystatinCatherosclerosis and lipid-lowering therapy by statins2011p187–204Search in Google Scholar
Korolenko TA, Pisareva EE, Filyushina EE, Johnston TP, Machova E. Serum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: can they serve as potential early biomarkers for atherosclerosis? Exp Toxicol Pathol 2015; 67: 459-66. doi: 10.1016/j.etp.2015.06.003KorolenkoTAPisarevaEEFilyushinaEEJohnstonTPMachovaESerum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: can they serve as potential early biomarkers for atherosclerosis?2015674596610.1016/j.etp.2015.06.00326129870Open DOISearch in Google Scholar
Paraoan L, Gray D, Hiscott P, Garcia-Finana M, Lane B, Damato B, et al. Cathepsin S and its inhibitor cystatin C: imbalance in uveal melanoma. Front Biosci (Landmark Ed.) 2009; 14: 2504-13. doi: 10.2741/3393ParaoanLGrayDHiscottPGarcia-FinanaMLaneBDamatoBet alCathepsin S and its inhibitor cystatin C: imbalance in uveal melanoma20091425041310.2741/339319273215Open DOISearch in Google Scholar
De Souza GA, Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol 2006; 7: R72. doi: 10.1186/gb-2006-7-8-R72DeSouza GAGodoyLMMannMIdentification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors20067R7210.1186/gb-2006-7-8-R72177960516901338Open DOISearch in Google Scholar
Balasubramanian SA, Wasinger VC, Pye DC, Willcox MD. Preliminary identification of differentially expressed tear proteins in keratoconus. Mol Vis 2013; 19: 2124-34. eCollection 2013. PMID: 24194634BalasubramanianSAWasingerVCPyeDCWillcoxMDPreliminary identification of differentially expressed tear proteins in keratoconus201319212434eCollection 2013. PMID: 24194634Search in Google Scholar
Dikovskaya MA, Trunov AN, Chernykh VV, Korolenko TA. Cystatin C and lactoferrin concentrations in biological fluids as possible prognostic factors in eye tumor development. Int J Circumpolar Health 2013; 72(Suppl 1): 21087. doi: 10.3402/ijch.v72i0.21087. eCollection 2013DikovskayaMATrunovANChernykhVVKorolenkoTACystatin C and lactoferrin concentrations in biological fluids as possible prognostic factors in eye tumor development201372Suppl 12108710.3402/ijch.v72i0.21087.eCollection2013Open DOISearch in Google Scholar
Korolenko TA, Tuzikov FV, Cherkanova MS, Johnston TP, Tuzikova NA, Loginova VM, et al. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407. Can J Physiol Pharmacol 2012; 90: 141-53. doi: 10.1139/y11-118KorolenkoTATuzikovFVCherkanovaMSJohnstonTPTuzikovaNALoginovaVMet alInfluence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 4072012901415310.1139/y11-11822320860Open DOISearch in Google Scholar
Pišlar A, Jewett A, Kos J. Cysteine cathepsins: their biological and molecular significance in cancer stem cells. Semin Cancer Biol 2018; 53: 168-77. doi: 10.1016/j.semcancer.2018.07.010PišlarAJewettAKosJCysteine cathepsins: their biological and molecular significance in cancer stem cells2018531687710.1016/j.semcancer.2018.07.01030063965Open DOISearch in Google Scholar
Jiang J, Liu HL, Liu ZH, Tan SW, Wu B. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumor Biol 2015; 36: 3903-10. doi: 10.1007/s13277-014-3033-3JiangJLiuHLLiuZHTanSWWuBIdentification of cystatin SN as a novel biomarker for pancreatic cancer20153639031010.1007/s13277-014-3033-325577248Open DOISearch in Google Scholar
Jiang Y, Zhang J, Zhang C, Hong L, Jiang Y, Lu L, et al. The role of cystatin C as a proteosome inhibitor in multiple myeloma. Hematology 2020; 25: 457-63. doi: 10.1080/16078454.2020.1850973JiangYZhangJZhangCHongLJiangYLuLet alThe role of cystatin C as a proteosome inhibitor in multiple myeloma2020254576310.1080/16078454.2020.185097333250014Open DOISearch in Google Scholar
Leto G, Sepporta MV. The potential of cystatin C as a predictive biomarker in breast cancer. Expert Rev Anticancer Ther 2020; 20: 1049-56. doi: 10.1080/14737140.2020.1829481LetoGSepportaMVThe potential of cystatin C as a predictive biomarker in breast cancer20202010495610.1080/14737140.2020.182948132990495Open DOISearch in Google Scholar
Ognibene A, Mannucci E, Caldini A, Terreni A, Brogi M, Bardini G, et al. Cystatin C reference values and aging. Clin Biochem 2006; 39: 658-61. doi: 10.1016/j.clinbiochem.2006.03.017OgnibeneAMannucciECaldiniATerreniABrogiMBardiniGet alCystatin C reference values and aging2006396586110.1016/j.clinbiochem.2006.03.01716730690Open DOISearch in Google Scholar
Odden MC, Tager IB, Gansevoort RT, Bakker SJ, Katz R, Fried LF, et al. Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant 2010; 25: 463-9. doi: 10.1093/ndt/gfp474OddenMCTagerIBGansevoortRTBakkerSJKatzRFriedLFet alAge and cystatin C in healthy adults: a collaborative study201025463910.1093/ndt/gfp474290424819749145Open DOISearch in Google Scholar
Edinga BE, Yakam AT, Nansseu JR, Bilong C, Belinga S, Minkala E, et al. Reference intervals for serum cystatin C and serum creatinine in an adult sub-Saharan African population. BMC Clin Pathol 2019; 19: 4. doi: 10.1186/ s12907-019-0086-7EdingaBEYakamATNansseuJRBilongCBelingaSMinkalaEet alReference intervals for serum cystatin C and serum creatinine in an adult sub-Saharan African population201919410.1186/s12907-019-0086-7642379630923459Open DOISearch in Google Scholar
Groesbeck D, Köttgen A, Parekh R, Selvin E, Schwartz GJ, Coresh J, et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol 2008; 3: 1777-85. doi: 10.2215/CJN.00840208GroesbeckDKöttgenAParekhRSelvinESchwartzGJCoreshJet alAge, gender, and race effects on cystatin C levels in US adolescents2008317778510.2215/CJN.00840208257227918815241Open DOISearch in Google Scholar
Zou J, Chen Z, Wei X, Chen Z, Fu Y, Yang X, et al. Cystatin C as a potential therapeutic mediator against Parkinson’s disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. Cell Death Dis 2017; 8: e2854. doi: 10.1038/cddis.2017.240ZouJChenZWeiXChenZFuYYangXet alCystatin C as a potential therapeutic mediator against Parkinson’s disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units20178e285410.1038/cddis.2017.240552089928569795Open DOISearch in Google Scholar
Keppler D, Zhang J, Bihani T, Lin AW. Novel expression of CST1 as candidate senescence marker. J Gerontol A Biol Sci Med Sci 2011; 66: 723-31. doi: 10.1093/gerona/glr033KepplerDZhangJBihaniTLinAWNovel expression of CST1 as candidate senescence marker2011667233110.1093/gerona/glr03321636832Open DOISearch in Google Scholar
Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, et al. Plasma cystatin C and high-density lipoprotein are important biomarkers of Alzheimer’s disease and vascular dementia: a cross-sectional study. Front Aging Neurosci 2017; 9: 26. doi: 10.3389/fnagi.2017.00026WangRChenZFuYWeiXLiaoJLiuXet alPlasma cystatin C and high-density lipoprotein are important biomarkers of Alzheimer’s disease and vascular dementia: a cross-sectional study201792610.3389/fnagi.2017.00026529492128223934Open DOISearch in Google Scholar
Xu Y, Ding Y, Li X, Wu X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol 2015; 93: 442-51. doi: 10.1038/ icb.2014.121XuYDingYLiXWuXCystatin C is a disease-associated protein subject to multiple regulation2015934425110.1038/icb.2014.121716592925643616Open DOISearch in Google Scholar
Kos J, Mitrović A, Mirković B. The current stage of cathepsin B inhibitors as potential anticancer agents. Future Med Chem 2014; 6: 1355-71. doi: 10.4155/fmc.14.73KosJMitrovićAMirkovićBThe current stage of cathepsin B inhibitors as potential anticancer agents2014613557110.4155/fmc.14.7325163003Open DOISearch in Google Scholar
Pieragostino D, D’Alessandro M, Di Ioia M, Di Ilio C, Sacchetta P, Del Boccio P. Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases. Proteomics Clin Appl 2015; 9: 169-86. doi: 10.1002/ prca.201400084PieragostinoDD’AlessandroMDiIoia MDiIlio CSacchettaPDelBoccio PUnraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases201591698610.1002/prca.20140008425488355Open DOISearch in Google Scholar
Huh CG, Håkansson K, Nathanson CM, Thorgeirsson UP, Jonsson N, Grubb A, et al. Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol Pathol 1999; 52: 332-40. doi: 10.1136/mp.52.6.332HuhCGHåkanssonKNathansonCMThorgeirssonUPJonssonNGrubbAet alDecreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene1999523324010.1136/mp.52.6.33239571810748866Open DOISearch in Google Scholar
Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS ONE 2009; 4: e7953. doi: 10.1371/journal.pone.0007953WegielBJibornTAbrahamsonMHelczynskiLOtterbeinLPerssonJLet alCystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways20094e795310.1371/journal.pone.0007953277651519956729Open DOISearch in Google Scholar
Hammouda NE, Salah El-Din MA, El-Shishtawy MM, El-Gayar AM. Serum cystatin C as a biomarker in diffuse large B-cell lymphoma. Sci Pharm 2017; 85: 9. doi: 10.3390/scipharm85010009HammoudaNESalahEl-Din MAEl-ShishtawyMMEl-GayarAMSerum cystatin C as a biomarker in diffuse large B-cell lymphoma201785910.3390/scipharm85010009538814628282874Open DOISearch in Google Scholar
Cao X, Li Y, Luo RZ, Zhang L, Zhang SL, Zeng J, et al. Expression of cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients. Sci Rep 2015; 5: 8230. doi: 10.1038/srep08230CaoXLiYLuoRZZhangLZhangSLZengJet alExpression of cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients20155823010.1038/srep08230431617225648368Open DOISearch in Google Scholar
Chen YF, Ma G, Cao X, Luo RZ, He LR, He JH, et al. Overexpression of cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma. BMC Surg 2013; 13: 15. doi: 10.1186/1471-248213-15ChenYFMaGCaoXLuoRZHeLRHeJHet alOverexpression of cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma2013131510.1186/1471-248213-15Open DOISearch in Google Scholar
Oh SS, Park S, Lee KW, Madhi H, Park SG, Lee HG, et al. Extracellular cystatin SN and cathepsin B prevent cellular senescence by inhibiting abnormal glycogen accumulation. Cell Death Dis 2017; 8: e2729. doi: 10.1038/cddis.2017.153OhSSParkSLeeKWMadhiHParkSGLeeHGet alExtracellular cystatin SN and cathepsin B prevent cellular senescence by inhibiting abnormal glycogen accumulation20178e272910.1038/cddis.2017.153547757928383558Open DOISearch in Google Scholar
Oh BM, Lee SJ, Cho HJ, Park YS, Kim JT, Yoon SR, et al. Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer. Cell Death Dis 2017; 8: e2682. doi: 10.1038/cddis.2017.100OhBMLeeSJChoHJParkYSKimJTYoonSRet alCystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer20178e268210.1038/cddis.2017.100538651228300829Open DOISearch in Google Scholar
Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, et al. Identification of cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009; 35: 33-40. doi: 10.3892/ijo_00000310YonedaKIidaHEndoHHosonoKAkiyamaTTakahashiHet alIdentification of cystatin SN as a novel tumor marker for colorectal cancer200935334010.3892/ijo_00000310Open DOISearch in Google Scholar
Cui Y, Sun D, Song R, Zhang S, Liu X, Wang Y, et al. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis. J Cell Physiol 2019; 234: 22623-34. doi: 10.1002/jcp.28828CuiYSunDSongRZhangSLiuXWangYet alUpregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis2019234226233410.1002/jcp.28828676755831106426Open DOISearch in Google Scholar
Paraoan L, Hiscott P, Gosden C. Cystatin C in macular and neuronal degenerations: Implications for mechanism(s) of age-related macular degeneration. Vision Research 2010; 50: 737-42. doi: 10.1016/j.visres.2009.10.022ParaoanLHiscottPGosdenCCystatin C in macular and neuronal degenerations: Implications for mechanism(s) of age-related macular degeneration2010507374210.1016/j.visres.2009.10.02219917302Open DOISearch in Google Scholar